Professional Documents
Culture Documents
Similar pathophysiology
Similar presentation and early management rules STEMI requires evaluation for acute reperfusion intervention
Elevation MI (NSTEMI)
ST-Segment
Elevation MI (STEMI)
Pathophysiology of Atherosclerosis
Endothelial Dysfunction
Foam Cells
oxidized LDL homocysteine smoking aging hyperglycemia hypertension
35-45 yrs 45-55 yrs Lipid accumulation Endothelial adhesion molecules injury (ICAM, VCAM)
nitric oxide endothelin-1 vasodilation monocyte adhesion macrophage LDL uptake
55-65 yrs
>65 yrs
MMP's CRP (hepatic)
Inflammation
continued macrophage/lipid accumulation leukocyte accumulation cytokines (IL-6,TNFa, IFNg)
Unstable plaque
Media
Stable plaque
Atherosclerosis
CAD Myocardial Ischemia
Coronary Thrombosis
Myocardial Infarction Arrhythmia & Loss of Muscle Remodeling Ventricular Dilation Congestive Heart Failure Endstage Heart Disease
Modifiable
Dyslipidemia (LDL ,HDL) Tobacco smoking Hypertension Diabetes Mellitus, Metabolic Syndrome Lack of Physical Activity
Non Modifiable
Advanced age Male gender (post menopausal women) Family history (1st degree relatives <55 male or <65 female)
Novel
Homocysteine Lipoprotein (a) CRP & other inflammatory markers
Kematian PJK
500
0
Russia Poland Finland New England/ USA Zealand Wales Italy Spain Japan
Mortality (%) *Ischemic heart disease, cerebrovascular disease, inflammatory heart disease and hypertensive heart disease Worldwide defined as Member States by WHO Region (African, Americas, Eastern Mediterranean, European, South-East Asia and Western Pacific)
1. The World Health Report, 2002, WHO Geneva, 2002.
Merokok
Hipertensi Hiperkolesterol D M
following Ischemic symptoms Diagnostic ECG changes Serum cardiac marker elevations
Diagnosis of Angina
Typical anginaAll three of the following
Substernal chest discomfort Onset with exertion or emotional stress Relief with rest or nitroglycerin
Atypical angina
1 of the above
arm, left shoulder, interscapular, infrascapular, epigastric Character : Tightness,pressure,burning, heaviness, aching, strangling, compression Dull & deep
frequency Exacerbating & alleviating factors 4 Es : Exercise, Emotional Stress, Exposure to Cold/Hot humid, Eating Relieved by : rest, relax, SL/NTG Associated symptoms : breath shortness, sweating, dizziness, syncope, fatique
Unstable Angina
Non occlusive thrombus
NSTEMI
Occluding thrombus sufficient to cause tissue damage & mild myocardial necrosis ST depression +/T wave inversion on ECG Elevated cardiac enzymes
STEMI
Complete thrombus occlusion ST elevations on ECG or new LBBB Elevated cardiac enzymes More severe symptoms
Emergent care
IV access Cardiac monitoring Oxygen Aspirin Nitrates
History & Physical Establish diagnosis Read ECG Identify complications Assess for reperfusion
12 lead ECG Obtain initial cardiac enzymes electrolytes, cbc, lipids, bun/cr, glucose, CXR
Targeted Physical
Examination Recognize factors that
increase risk
Hypotension Tachycardia Pulmonary rales, JVD, pulmonary edema, New murmurs/heart sounds Diminished peripheral pulses Signs of stroke
NSTEMI
Non-specific ECG
Unstable Angina
ST-Segment Elevation MI
Historical Age 65-74 >75 DM/HTN/Angina Exam SBP < 100 mmHg HR > 100 bpm Killip II IV Weight < 67 kg
35,9 26,8
10
0,8
0
1,6 1
Presentation Anterior STE or LBBB 1 pt Time to Rx > 4hr 1pt -----------------------------------Risk Score = Total (0-14)
>8
TIMI 17
Mortality
35%
Mild to moderate orthopnea S3 gallop Bibasilar rales 50% of both lung fields Severe Respiratory Distress Rales over >50% of both lung fields X-ray:interstitial & alveolar edema
Hypotension (BP systolic <90mmHg) Tachycardia Signs of peripheral perfusion
6 10 %
20 30 %
>80 %
Cardiac markers
Troponin ( T, I)
CK-MB isoenzyme
Very specific and more sensitive than CK Rises 4-8 hours after injury May remain elevated for up to two weeks Can provide prognostic information Troponin T may be elevated with renal dz, poly/dermatomyositis
Rises 4-6 hours after injury and peaks at 24 hours Remains elevated 36-48 hours Positive if CK/MB > 5% of total CK and 2 times normal Elevation can be predictive of mortality False positives with exercise, trauma, muscle dz, DM, PE
Shapiro BP, Jaffe AS. Cardiac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo Clinic Cardiology: Concise Textbook. 3 rd ed. Rochester, MN: Mayo Clinic Scientific Press and New York: Informa Healthcare USA, 2007:77380. Anderson JL, et al. J Am Coll Cardiol 2007;50:e1e157, Figure 5.
32
STEMI
Reperfusion Approach
Aspirin Heparin (UFH/LMWH) Clopidogrel Reperfusion method :
A.Fibrinolytic B.Primary PCI (+GPIIb/IIIa inhibitor)
UAP/NSTEMI
All patients
General :
Pain control (morphine) Oxygen
Antithrombotic Approach
Aspirin Heparin (UFH/LMWH) Clopidogrel For high risk patients :
GP IIb/IIIa inhibitor Cardiac cath
Anti ischemic :
blocker Nitrates +/- Ca blocker
Additional :
ACE inhibitor Statins
Decrease amount of myocardial necrosis Preserve LV function Prevent major adverse cardiac events Treat life threatening complications
Fibrinolysis indications
ST segment elevation >1mm in two contiguous
leads New LBBB Symptoms consistent with ischemia Symptom onset less than 12 hrs prior to presentation
- 1.5 millions unit in 100 ml normal saline IV over 1 hour - No indication for routine heparinization after SK Recombinant Tissue-type plasminogen activator (rTPA, alteplase) - 15 mg bolus IV then 0.75 mg/ kg over 30 minutes (not to exceed 50 mg), then 0.5 mg/ kg over 60 minutes (not to exceed 35 mg)
Reteplase
- Two IV bolus doses of 10 units 10 minutes apart Tenectaplase - As injection over 10 seconds at 30 50 mg according to body weight - Maximum dose is 50 mg APSAC (Anistreplase) - IV bolus of 30 mg over 2 5 minutes
(primary or metastatic) Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours Suspected aortic dissection Active bleeding or bleeding diathesis (excluding menses) Significant closed-head or facial trauma within 3 months
hypertension Severe uncontrolled hypertension on presentation (SBP greater than 180 mm Hg or DBP greater than 110 mmHg) History of prior ischemic stroke greater than 3 months, dementia, or known intracranial pathology not covered in contraindications Traumatic or prolonged (greater than 10 minutes) CPR or major surgery (less than 3 weeks)
Recent (within 2-4 weeks) internal bleeding Noncompressible vascular punctures For streptokinase/anistreplase: prior exposure
(more than 5 days ago) or prior allergic reaction to these agents Pregnancy Active peptic ulcer Current use of anticoagulants: the higher the INR, the higher the risk of bleeding
STEMI dx in doubt
Analgesia Reduce pain/anxietydecrease sympathetic tone, systemic vascular resistance and oxygen demand Careful with hypotension, hypovolemia, respiratory depression
Up to 70% of ACS patient demonstrate hypoxemia May limit ischemic myocardial damage by increasing oxygen delivery/reduce ST elevation
Analgesiatitrate infusion to keep patient pain free Dilates coronary vesselsincrease blood flow Reduces systemic vascular resistance and preload Careful with recent ED meds, hypotension, bradycardia, tachycardia, RV infarction
Irreversible inhibition of platelet aggregation Stabilize plaque and arrest thrombus Reduce mortality in patients with STEMI Careful with active PUD, hypersensitivity, bleeding disorders
14% reduction in mortality risk at 7 days at 23% long term mortality reduction in STEMI Approximate 13% reduction in risk of progression to MI in patients with threatening or evolving MI symptoms Be aware of contraindications (CHF, Heart block, Hypotension) Reassess for therapy as contraindications resolve
Start in patients with anterior MI, pulmonary congestion, LVEF < 40% in absence of contraindication/hypotension Start in first 24 hours ARB as substitute for patients unable to use ACE-I
Irreversible inhibition of platelet aggregation Used in support of cath / PCI intervention or if unable to take aspirin 3 to 12 month duration depending on scenario
Inhibition of platelet aggregation at final common pathway In support of PCI intervention as early as possible prior to PCI
Indirect inhibitor of thrombin less supporting evidence of benefit in era of reperfusion Adjunct to surgical revascularization and thrombolytic / PCI reperfusion 24-48 hours of treatment Coordinate with PCI team (UFH preferred) Used in combo with aspirin and/or other platelet inhibitors Changing from one to the other not recommended
Risk of actual ACS TIMI risk score ACS risk categories per AHA guidelines
Low
Intermediate
High
Low risk
Intermediate
risk
High risk
Conservative therapy
Invasive therapy
within 12 to 48 hours after presentation to ED For high risk ACS (class I, level A) MONA + BAH (UFH) Clopidogrel
20% reduction death/MI/Stroke CURE trial 1 month minimum duration and possibly up to 9 months
Complications of ACS
Acute cardiac failure Cardiogenic shock
Cardiac tamponade
Ventricular septal defect Papillary muscle rupture
Pericarditis
Secondary Prevention
Disease
Behavioral
Cognitive
Summary
ACS includes UA, NSTEMI, and STEMI Management guideline focus
Immediate assessment/intervention (MONA+BAH) Risk stratification (UA/NSTEMI vs. STEMI) RAPID reperfusion for STEMI (PCI vs. Thrombolytics) Conservative vs Invasive therapy for UA/NSTEMI